Evidence map›Paper›PMID 23778475›Full record

ArticleClinics (Sao Paulo, Brazil)2013

Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer.

Daniela Teixeira, Joaquim Soares de Almeida, Bruna Visniauskas, Guiomar Nascimento Gomes, Aparecida Emiko Hirata, Valquiria Bueno

Open access · goldAbstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniela TeixeiraFederal University of São Paulo, Immunology Division, São Paulo/SP, Brazil.
Joaquim Soares de Almeida
Bruna Visniauskas
Guiomar Nascimento Gomes
Aparecida Emiko Hirata
Valquiria Bueno
Universidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMyeloid-derived suppressor cells contribute to the immunosuppressive microenvironment during tumor development and limit the efficacy of cancer immunotherapy. Identifying myeloid-derived suppressor cells and associated factors is the first step in creating strategies to reverse the suppressive effects of these cells on the immune system.

methodsTo induce lung cancer, we administered 2 doses of urethane to BALB/c mice and observed these animals for 120 days. After this period, we evaluated the percentage of myeloid-derived suppressor cells in the blood, lung and bone marrow. The expression of alpha-smooth muscle actin, transforming growth factor-β, Toll-like receptor 2, Toll-like receptor 4, and interleukin-6 was also determined in the lung tissue.

resultsMyeloid-derived suppressor cells were increased in all evaluated tissues after lung cancer development in association with increased Toll-like receptor 4 expression and decreased interleukin-6 expression in the lung. We observed alpha-smooth muscle actin and transforming growth factor-β expression in lung nodules.

conclusionsWe believe that the early diagnosis of cancer through determining the blood levels of myeloid-derived suppressor cells followed by the depletion of these cells should be further investigated as a possible approach for cancer treatment.

Indexed as

ActinsAnimalsBlotting, WesternCarcinogensFlow CytometryImmunohistochemistryInterleukin-6LungLung NeoplasmsMaleMiceMice, Inbred BALB CMyeloid CellsTime FactorsToll-Like Receptor 4UrethaneActinsalpha-smooth muscle actin, mouseCarcinogensInterleukin-6interleukin-6, mouseTlr4 protein, mouseToll-Like Receptor 4Urethane

Identifiers

PMID23778475
PMCPMC3674301
OpenAlexW1994123661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.